Heart failure (HF) is a chronic condition characterized by the heart’s inability to pump blood effectively. Hypertension is a frequent contributing factor. The reduced cardiac output leads to fluid accumulation, causing respiratory distress and chest pain. Ejection fraction (EF), a measure of the left ventricle’s pumping capacity, is crucial in HF diagnosis. HF with reduced EF (HFrEF) is defined by an EF below 40%, often caused by coronary artery disease—approximately half of all HF patients present with HFrEF. The remaining cases encompass HF with mid-range EF (40% - 50%) or HF with preserved EF (HFpEF, EF ≥ 50%).
References
[1]
Angermann, C.E. (2009) Comorbidities in Heart Failure: A Key Issue. European Journal of Heart Failure Supplements, 8, i5-i10. https://doi.org/10.1093/eurjhf/hfp009
[2]
Ponikowski, P., Anker, S.D., AlHabib, K.F., Cowie, M.R., Force, T.L., Hu, S., et al. (2014) Heart Failure: Preventing Disease and Death Worldwide. ESC Heart Failure, 1, 4-25. https://doi.org/10.1002/ehf2.12005
[3]
Borlaug, B.A. (2014) The Pathophysiology of Heart Failure with Preserved Ejection Fraction. Nature Reviews Cardiology, 11, 507-515. https://doi.org/10.1038/nrcardio.2014.83
[4]
Xanthopoulos, A., Triposkiadis, F. and Starling, R.C. (2018) Heart Failure with Preserved Ejection Fraction: Classification Based upon Phenotype Is Essential for Diagnosis and Treatment. Trends in Cardiovascular Medicine, 28, 392-400. https://doi.org/10.1016/j.tcm.2018.01.001
[5]
Cao, J., Dong, R., Zhang, K. and Zhang, H. (2020) Effects of Myocardial Viability and Left Ventricular Remodeling on Survival of Patients with Heart Failure and Reduced Ejection Fraction after Coronary Artery Bypass Grafting. Cardiovascular Diagnosis and Therapy, 10, 183-192. https://doi.org/10.21037/cdt.2020.01.11
[6]
Rashid, A.M., Khan, M.S., Fudim, M., DeWald, T.A., DeVore, A. and Butler, J. (2023) Management of Heart Failure with Reduced Ejection Fraction. Current Problems in Cardiology, 48, Article ID: 101596. https://doi.org/10.1016/j.cpcardiol.2023.101596
[7]
Dalén, M., Lund, L.H., Ivert, T., Holzmann, M.J. and Sartipy, U. (2016) Survival after Coronary Artery Bypass Grafting in Patients with Preoperative Heart Failure and Preserved vs Reduced Ejection Fraction. JAMA Cardiology, 1, 530-538. https://doi.org/10.1001/jamacardio.2016.1465
[8]
Upadhya, B., Taffet, G.E., Cheng, C.P. and Kitzman, D.W. (2015) Heart Failure with Preserved Ejection Fraction in the Elderly: Scope of the Problem. Journal of Molecular and Cellular Cardiology, 83, 73-87. https://doi.org/10.1016/j.yjmcc.2015.02.025
[9]
Mann, D.L. (2008) Management of Heart Failure Patients with Reduced Ejection Fraction. In: Zipes, D.P., et al., Eds., Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 8th Edition, WB Saunders, 611-640.
[10]
Tschöpe, C., Birner, C., Böhm, M., Bruder, O., Frantz, S., Luchner, A., et al. (2017) Heart Failure with Preserved Ejection Fraction: Current Management and Future Strategies. Clinical Research in Cardiology, 107, 1-19. https://doi.org/10.1007/s00392-017-1170-6
[11]
White, H.D., Norris, R.M., Brown, M.A., Brandt, P.W., Whitlock, R.M. and Wild, C.J. (1987) Left Ventricular End-Systolic Volume as the Major Determinant of Survival after Recovery from Myocardial Infarction. Circulation, 76, 44-51. https://doi.org/10.1161/01.cir.76.1.44
[12]
Kemp, C.D. and Conte, J.V. (2012) The Pathophysiology of Heart Failure. Cardiovascular Pathology, 21, 365-371. https://doi.org/10.1016/j.carpath.2011.11.007
[13]
Piano, M.R., Bondmass, M. and Schwertz, D.W. (1998) The Molecular and Cellular Pathophysiology of Heart Failure. Heart & Lung, 27, 3-19. https://doi.org/10.1016/s0147-9563(98)90063-2
[14]
Abudiab, M.M., Redfield, M.M., Melenovsky, V., Olson, T.P., Kass, D.A., Johnson, B.D., et al. (2013) Cardiac Output Response to Exercise in Relation to Metabolic Demand in Heart Failure with Preserved Ejection Fraction. European Journal of Heart Failure, 15, 776-785. https://doi.org/10.1093/eurjhf/hft026
[15]
Becher, P.M., Lund, L.H., Coats, A.J.S. and Savarese, G. (2022) An Update on Global Epidemiology in Heart Failure. European Heart Journal, 43, 3005-3007. https://doi.org/10.1093/eurheartj/ehac248
[16]
Pölzl, L., Nägele, F., Graber, M., Hirsch, J., Lobenwein, D., Mitrovic, M., et al. (2020) Safety and Efficacy of Direct Cardiac Shockwave Therapy in Patients with Ischemic Cardiomyopathy Undergoing Coronary Artery Bypass Grafting (The CAST-HF Trial): Study Protocol for a Randomized Controlled Trial. Trials, 21, Article No. 447. https://doi.org/10.1186/s13063-020-04369-0
[17]
Vaikunth, S.S. and Lui, G.K. (2019) Heart Failure with Reduced and Preserved Ejection Fraction in Adult Congenital Heart Disease. Heart Failure Reviews, 25, 569-581. https://doi.org/10.1007/s10741-019-09904-z
[18]
Khabibovna, Y.S., Alisherovna, K.M., Nizamitdinovich, K.S. and Totlibayevich, Y.S. (2023) Features of Heart Failure in Patients with Thyrotoxicosis. Journal of New Century Innovations, 29, 89-97.
[19]
Velazquez, E.J. and Bonow, R.O. (2015) Revascularization in Severe Left Ventricular Dysfunction. Journal of the American College of Cardiology, 65, 615-624. https://doi.org/10.1016/j.jacc.2014.10.070
[20]
Wickman, B.E., Enkhmaa, B., Ridberg, R., Romero, E., Cadeiras, M., Meyers, F., et al. (2021) Dietary Management of Heart Failure: DASH Diet and Precision Nutrition Perspectives. Nutrients, 13, Article No. 4424. https://doi.org/10.3390/nu13124424
[21]
Jørgensen, T., Borch-Johnsen, K., Thomsen, T.F., Ibsen, H., Glümer, C. and Pisinger, C. (2003) A Randomized Non-Pharmacological Intervention Study for Prevention of Ischaemic Heart Disease: Baseline Results Inter99 (1). European Journal of Cardiovascular Prevention & Rehabilitation, 10, 377-386. https://doi.org/10.1097/01.hjr.0000096541.30533.82
[22]
Pölzl, L., Thielmann, M., Cymorek, S., Nägele, F., Hirsch, J., Graber, M., et al. (2022) Impact of Myocardial Injury after Coronary Artery Bypass Grafting on Long-Term Prognosis. European Heart Journal, 43, 2407-2417. https://doi.org/10.1093/eurheartj/ehac054
[23]
Pischke, C.R., Elliott-Eller, M., Li, M., Mendell, N., Ornish, D. and Weidner, G. (2010) Clinical Events in Coronary Heart Disease Patients with an Ejection Fraction of 40% or Less. Journal of Cardiovascular Nursing, 25, E8-E15. https://doi.org/10.1097/jcn.0b013e3181d51f9e
[24]
Dashti, H.M., Bo-Abbas, Y.Y., Asfar, S.K., Mathew, T.C., Hussein, T., Behbahani, A., et al. (2003) Ketogenic Diet Modifies the Risk Factors of Heart Disease in Obese Patients. Nutrition, 19, 901-902. https://doi.org/10.1016/s0899-9007(03)00161-8
[25]
Berliner, D. and Bauersachs, J. (2017) Current Drug Therapy in Chronic Heart Failure: The New Guidelines of the European Society of Cardiology (ESC). Korean Circulation Journal, 47, 543-554. https://doi.org/10.4070/kcj.2017.0030
[26]
Shah, S.J., Kitzman, D.W., Borlaug, B.A., van Heerebeek, L., Zile, M.R., Kass, D.A., et al. (2016) Phenotype-Specific Treatment of Heart Failure with Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation, 134, 73-90. https://doi.org/10.1161/circulationaha.116.021884
[27]
Jacob, M., Reddy, R.P., Garcia, R.I., Reddy, A.P., Khemka, S., Roghani, A.K., et al. (2024) Harnessing Artificial Intelligence for the Detection and Management of Colorectal Cancer Treatment. Cancer Prevention Research, 17, 499-515. https://doi.org/10.1158/1940-6207.capr-24-0178
[28]
Assmus, B., Walter, D.H., Seeger, F.H., Leistner, D.M., Steiner, J., Ziegler, I., et al. (2013) Effect of Shock Wave-Facilitated Intracoronary Cell Therapy on LVEF in Patients with Chronic Heart Failure: The CELLWAVE Randomized Clinical Trial. JAMA, 309, 1622-1631. https://doi.org/10.1001/jama.2013.3527
[29]
Jones, R.H., Velazquez, E.J., Michler, R.E., Sopko, G., Oh, J.K., O’Connor, C.M., et al. (2009) Coronary Bypass Surgery with or without Surgical Ventricular Reconstruction. New England Journal of Medicine, 360, 1705-1717. https://doi.org/10.1056/nejmoa0900559
[30]
Hoang, C.V., Dang, T.N., Nguyen, D.N. and To, K.G. (2023) Knowledge, Treatment Adherence, and Quality of Life of Heart Failure Patients at Nhan Dan Gia Dinh Hospital. MedPharmRes, 7, 102-110. https://doi.org/10.32895/ump.mpr.7.4.13
[31]
Dinu, M., Pagliai, G. and Sofi, F. (2017) A Heart-Healthy Diet: Recent Insights and Practical Recommendations. Current Cardiology Reports, 19, Article No. 95. https://doi.org/10.1007/s11886-017-0908-0
[32]
Yang, Y., Gao, J., Qin, Z., Lu, Y., Xu, Y., Guo, J., et al. (2023) The Present Clinical Treatment and Future Emerging Interdisciplinary for Heart Failure: Where We Are and What We Can Do. Intensive Care Research, 3, 3-11. https://doi.org/10.1007/s44231-023-00029-4
[33]
Bozkurt, B. (2024) Contemporary Pharmacological Treatment and Management of Heart Failure. Nature Reviews Cardiology, 21, 545-555. https://doi.org/10.1038/s41569-024-00997-0
[34]
Mullens, W., Dauw, J., Gustafsson, F., Mebazaa, A., Steffel, J., Witte, K.K., et al. (2024) Integration of Implantable Device Therapy in Patients with Heart Failure. a Clinical Consensus Statement from the heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). European Journal of Heart Failure, 26, 483-501. https://doi.org/10.1002/ejhf.3150
[35]
Yan, D., Zhan, S., Guo, C., Han, J., Zhan, L., Zhou, Q., et al. (2024) The Role of Myocardial Regeneration, Cardiomyocyte Apoptosis in Acute Myocardial Infarction: A Review of Current Research Trends and Challenges. Journal of Cardiology. https://doi.org/10.1016/j.jjcc.2024.09.012
[36]
Britto, M.F.d., Oliveira, A.L.M.d., Simões, R., Guimarães, N.S., Polese, J.C. and Souza, A.H.d. (2024) Adverse Events of the Use of SGLT2 Inhibitors in Patients with Heart Failure: A Systematic Review and Meta-Analysis. Journal of Advances in Medicine and Medical Research, 36, 65-76. https://doi.org/10.9734/jammr/2024/v36i75486
[37]
Alfieri, M., Bruscoli, F., Di Vito, L., Di Giusto, F., Scalone, G., Marchese, P., et al. (2024) Novel Medical Treatments and Devices for the Management of Heart Failure with Reduced Ejection Fraction. Journal of Cardiovascular Development and Disease, 11, Article No. 125. https://doi.org/10.3390/jcdd11040125
